Tag: CNS

Latest News

Oligodendrocyte Neurofascin Independently Regulates Both Myelin Targeting and Sheath Growth in the CNS

Newsemia
Klingseisen, A; Ristoiu, A-M; Kegel, L; Sherman, DL; Rubio-Brotons, M; Almeida, RG; Koudelka, S; … Lyons, DA; + view all Klingseisen, A; Ristoiu, A-M; Kegel,...
Pharma / Biotech

Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics.

Newsemia
Related Articles Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020 Jan...
Pharma / Biotech

Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part II. Pharmacodynamics of Electroencephalogram Effects.

Newsemia
Related Articles Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part II. Pharmacodynamics of Electroencephalogram Effects. Anesthesiology. 2020 Jan...
Neurology

Late 30s Could Be 'Critical Time' for Starting MS Therapy

Newsemia
A large study of patients with multiple sclerosis evaluated the interplay of age at disease onset and the timing of immunomodulatory therapy. Medscape Medical News...
Biology

NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity

Newsemia
by Marjan Gharagozloo, Shaimaa Mahmoud, Camille Simard, Kenzo Yamamoto, Diwakar Bobbala, Subburaj Ilangumaran, Matthew D. Smith, Albert Lamontagne, Samir Jarjoura, Jean-Bernard Denault, VĂ©ronique Blais, Louis...
Latest News

Global Central Nervous System (CNS) Stimulant Drugs Market Report 2019-2023 – Rising Demand to Legalize Cannabis Worldwide is a Key Market Driver – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The "Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The rise in CNS disorders CNS disorders...
Neurology

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

Newsemia
Related Articles Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by...
Latest News

Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new advances in its RNAi therapeutics platform, including preclinical results demonstrating...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World